Ultragenyx Pharma (RARE) PT Lowered to $47 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $17.16 +3.19%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $47.00 (from $48.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Ultragenyx Pharma (RARE) PT Raised to $19 at TD Cowen
- ONEOK Inc (OKE) PT Raised to $108 at Argus
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
